BioAtla (BCAB) FCF Margin (2020 - 2026)

BioAtla (BCAB) posted quarterly FCF Margin of 395.75% for Q4 2025, down 748.26% quarter-over-quarter from 46.65% in Q3 2024.

BioAtla (BCAB) FCF Margin (2020 - 2026) Analysis & Trends

BioAtla's FCF Margin history runs 4 years deep, the most recent figure standing at 395.75% for Q4 2025.

In Q4 2025, FCF Margin changed N/A year-over-year to 395.75%; the TTM figure through Dec 2025 stood at 370.8% (up 28316.0% YoY), while the FY2025 annual figure was 2410.2%, down 175624.0% from the prior year.
FCF Margin for Q4 2025 stood at 395.75%, down from 46.65% in the prior quarter.
The five-year high for FCF Margin was 46.65% in Q3 2024, with the low at 5234.4% in Q2 2021.
The 3-year median for FCF Margin is 395.75% (2025), against an average of 1892.27%.
Peak annual rise in FCF Margin reached 366440 bps in 2021, while the deepest fall reached 366440 bps in 2021.
BioAtla's FCF Margin stood at 5234.4% in 2021, then jumped by 99 bps to 46.65% in 2024, then plunged by 748 bps to 395.75% in 2025.
Business Quant data shows BCAB's FCF Margin at 395.75% in Q4 2025, 46.65% in Q3 2024, and 5234.4% in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	BioAtla	5.28 Mn	5.28 Mn	-	-6.45%

Download Data